Physician profile
Francis Soans
NPI 1861495632
$747.69
in general payments reported to CMS, 2019-2025
10 companies · $552 in 2025
The $552 reported for 2025 was less than what a typical Glaucoma Specialist provider received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.59 · 2020: $19.54 · 2023: $23.27 · 2024: $118 · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $692.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $141.02 | 2024-2025 | Miebo, Xiidra, Vyzulta |
| Alcon Vision LLC | $123.70 | 2024-2025 | Rocklatan, Rhopressa, Clareon |
| Astellas Pharma US INC | $120.72 | 2025 | Izervay |
| Genentech USA, INC. | $118.25 | 2025 | Susvimo |
| Abbvie INC. | $102.35 | 2023-2025 | Xen Glaucoma Treatment System |
| Ocular Therapeutix, INC. | $70.87 | 2025 | Dextenza |
| Optos, INC. | $19.54 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $17.92 | 2019 | |
| Aerie Pharmaceuticals, INC. | $17.67 | 2019 | |
| Sight Sciences, INC. | $15.65 | 2025 | Omni Surgical System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francis Soans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.